Navigation Links
Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma.

                           Conference Call Numbers

                              Wednesday, July 11

       1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European

                       1-800-240-7305 (US Participants)

                        1-303-262-2137 (International)


                            Live audio webcast at

                             www.cticseattle.com

                     will be archived for post listening

       approximately two hours after call ends, available for five days


     Call-back numbers for post listening available at 6:30 p.m. Eastern:

                       1-800-405-2236 (US Participants)

                        1-303-590-3000 (International)

                             Passcode: 11093505#


     Media Contact:


     Cell Therapeutics, Inc.

     Dan Eramian

     T: 206.272.4343

     C: 206.854.1200

     Susan Callahan

     T: 206.272.4472

     F: 206.272.4434

     E: 

     www.cticseattle.com/media.htm


     Investors Contact:


     Cell Therapeutics, Inc.

     Leah Grant

     T: 206.282.7100

     F: 206.272.4434

     E: 

     www.cticseattle.com/investors.htm

media@ctiseattle.com invest@ctiseattle.com

CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com

Web site: http://www.cticseattle.com//

Ticker Symbol: (NASDAQ-NMS:CTIC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
2. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
3. Choosing Lab Quality Management Software
4. Optimizing Quality Control Data Management
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
7. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
8. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
11. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Wegener Polyangiitis ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, ... Polyangiitis,s therapeutic pipeline. This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... SILVER SPRING, Md. , Feb. 4, 2016 ... Robert Califf , the FDA,s Deputy Commissioner for Medical Products ... far-reaching action plan to reassess the agency,s approach to opioid ... the epidemic, while still providing patients in pain access to ... The FDA will: , Re-examine the risk-benefit ...
Breaking Medicine Technology:
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):